Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 462

1.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, Yoshino T, Douillard JY.

Ann Oncol. 2020 Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Epub 2020 Jan 16.

PMID:
32081575
2.

Breast Cancer Provider Interval Length in Fukushima, Japan, After the 2011 Triple Disaster: A Long-Term Retrospective Study.

Ozaki A, Nomura S, Leppold C, Tsubokura M, Sawano T, Tsukada M, Morita T, Tanimoto T, Saji S, Kato S, Yamaoka K, Nakata Y, Ohira H.

Clin Breast Cancer. 2019 Sep 6. pii: S1526-8209(19)30652-4. doi: 10.1016/j.clbc.2019.07.008. [Epub ahead of print]

PMID:
31980405
3.

Hard plant tissues do not contribute meaningfully to dental microwear: evolutionary implications.

van Casteren A, Strait DS, Swain MV, Michael S, Thai LA, Philip SM, Saji S, Al-Fadhalah K, Almusallam AS, Shekeban A, McGraw WS, Kane EE, Wright BW, Lucas PW.

Sci Rep. 2020 Jan 17;10(1):582. doi: 10.1038/s41598-019-57403-w.

4.

Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report.

Gonda K, Akama T, Nakamura T, Hashimoto E, Kyoya N, Rokkaku Y, Maejima Y, Horita S, Tachibana K, Abe N, Ohtake T, Shimomura K, Kono K, Saji S, Takenoshita S, Higashihara E.

J Med Case Rep. 2019 Dec 24;13(1):381. doi: 10.1186/s13256-019-2274-6.

5.

Nicotine in E-cigarette smoke: cancer culprit?

Saji S, Patil SS, Alleyn M, Lockey R, Kolliputi N.

J Cell Commun Signal. 2019 Dec 18. doi: 10.1007/s12079-019-00519-5. [Epub ahead of print]

PMID:
31853716
6.

The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.

Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, Iwata H.

Breast Cancer. 2020 Jan;27(1):4-8. doi: 10.1007/s12282-019-01030-w. Epub 2019 Dec 12.

PMID:
31832890
7.

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.

Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y.

J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10.

PMID:
31821071
8.

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Breast Cancer. 2019 Dec 6. doi: 10.1007/s12282-019-01029-3. [Epub ahead of print]

PMID:
31811519
9.

The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient.

Iwata H, Saji S, Ikeda M, Inokuchi M, Uematsu T, Toyama T, Horii R, Yamauchi C.

Breast Cancer. 2020 Jan;27(1):1-3. doi: 10.1007/s12282-019-01021-x. Epub 2019 Nov 22.

PMID:
31758399
10.

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition.

Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, Hirokaga K, Yamaguchi K, Saji S, Iwata H.

Breast Cancer. 2020 Jan;27(1):17-24. doi: 10.1007/s12282-019-01025-7. Epub 2019 Nov 16.

PMID:
31734900
11.

The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition.

Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, Ogo E, Oguchi M, Saji S, Iwata H.

Breast Cancer. 2020 Jan;27(1):9-16. doi: 10.1007/s12282-019-01019-5. Epub 2019 Oct 28.

PMID:
31659711
12.

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.

Iwamoto T, Niikura N, Ogiya R, Yasojima H, Watanabe KI, Kanbayashi C, Tsuneizumi M, Matsui A, Fujisawa T, Iwasa T, Shien T, Saji S, Masuda N, Iwata H.

Sci Rep. 2019 Sep 16;9(1):13343. doi: 10.1038/s41598-019-50099-y.

13.

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.

Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M.

JAMA Oncol. 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Nov 1;5(11):1643. JAMA Oncol. 2019 Dec 19;:.

14.

Metallic proxies remain unsuitable for assessing the mechanics of microwear formation: reply to comment on van Casteren et al. (2018).

van Casteren A, Lucas PW, Strait DS, Michael S, Bierwisch N, Schwarzer N, Al-Fadhalah KJ, Almusallam AS, Thai LA, Saji S, Shekeban A, Swain MV.

R Soc Open Sci. 2019 Jul 10;6(7):190572. doi: 10.1098/rsos.190572. eCollection 2019 Jul. No abstract available.

15.

Color-coded Imaging of the Fate of Cancer-cell-derived Exosomes During Pancreatic Cancer Metastases in a Nude-mouse Model.

Satake T, Suetsugu A, Nakamura M, Kunisada T, Saji S, Moriwaki H, Shimizu M, Hoffman RM.

Anticancer Res. 2019 Aug;39(8):4055-4060. doi: 10.21873/anticanres.13561.

PMID:
31366487
16.

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30.

17.

Alda-1 attenuates hyperoxia-induced mitochondrial dysfunction in lung vascular endothelial cells.

Patil SS, Hernández-Cuervo H, Fukumoto J, Narala VR, Saji S, Borra M, Alleyn M, Lin M, Soundararajan R, Lockey R, Kolliputi N, Galam L.

Aging (Albany NY). 2019 Jun 17;11(12):3909-3918. doi: 10.18632/aging.102012.

18.

Drawing the mind: Aesthetics of representing mental illness in select graphic memoirs.

Venkatesan S, Saji S.

Health (London). 2019 May 13:1363459319846930. doi: 10.1177/1363459319846930. [Epub ahead of print]

PMID:
31081388
19.

MLH1 germline mutation associated with Lynch syndrome in a family followed for more than 45 years.

Momma T, Gonda K, Akama Y, Endo E, Ujiie D, Fujita S, Maejima Y, Horita S, Shimomura K, Saji S, Kono K, Yashima R, Watanabe F, Sugano K, Nomizu T.

BMC Med Genet. 2019 May 2;20(1):67. doi: 10.1186/s12881-019-0792-0.

20.

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.

ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. eCollection 2019.

21.

'It was nothing that you would think was anything': Qualitative analysis of appraisal and help seeking preceding brain cancer diagnosis.

Scott SE, Penfold C, Saji S, Curtis S, Watts C, Hamilton W, Joannides AJ, Walter FM.

PLoS One. 2019 Mar 22;14(3):e0213599. doi: 10.1371/journal.pone.0213599. eCollection 2019.

22.

Missed opportunities for diagnosing brain tumours in primary care: a qualitative study of patient experiences.

Walter FM, Penfold C, Joannides A, Saji S, Johnson M, Watts C, Brodbelt A, Jenkinson MD, Price SJ, Hamilton W, Scott SE.

Br J Gen Pract. 2019 Apr;69(681):e224-e235. doi: 10.3399/bjgp19X701861. Epub 2019 Mar 11.

23.

Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.

Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M, Imoto S.

Tumour Biol. 2018 Nov;40(10):1010428318811025. doi: 10.1177/1010428318811025.

PMID:
30841783
24.

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.

Tomita N, Kunieda K, Maeda A, Hamada C, Yamanaka T, Sato T, Yoshida K, Boku N, Nezu R, Yamaguchi S, Mishima H, Sadahiro S, Muro K, Ishiguro M, Sakamoto J, Saji S, Maehara Y.

Br J Cancer. 2019 Apr;120(7):689-696. doi: 10.1038/s41416-019-0410-0. Epub 2019 Mar 5.

25.

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M.

Int J Mol Sci. 2019 Feb 24;20(4). pii: E984. doi: 10.3390/ijms20040984.

26.

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials.

Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Sato Y, Maehara Y, Kanematsu T, Kitajima M.

Surg Today. 2019 Aug;49(8):704-711. doi: 10.1007/s00595-019-01787-9. Epub 2019 Feb 25.

27.

Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Honma N, Makita M, Saji S, Mikami T, Ogata H, Horii R, Akiyama F, Iwase T, Ohno S.

Support Care Cancer. 2019 Oct;27(10):3813-3822. doi: 10.1007/s00520-019-04674-8. Epub 2019 Feb 7.

PMID:
30729298
28.

Altered expression of p63 isoforms and expansion of p63- and club cell secretory protein-positive epithelial cells in the lung as novel features of aging.

Fukumoto J, Sidramagowda Patil S, Krishnamurthy S, Saji S, John I, Narala VR, Hernández-Cuervo H, Alleyn M, Breitzig MT, Galam L, Soundararajan R, Chaudhari UK, Hansen BC, Lockey RF, Kolliputi N.

Am J Physiol Cell Physiol. 2019 Apr 1;316(4):C492-C508. doi: 10.1152/ajpcell.00330.2018. Epub 2019 Jan 16.

29.

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7.

Suga J, Izumiyama K, Tanaka N, Saji S.

Biochem Biophys Rep. 2018 Oct 26;16:103-109. doi: 10.1016/j.bbrep.2018.10.008. eCollection 2018 Dec.

30.

[A Case of Recurrent Colon Cancer with Peritoneal Dissemination Treated with Aflibercept Showing Partial Response for One Year].

Gonda K, Fujita S, Shibata M, Hatakeyama Y, Tachiya Y, Rokkaku Y, Saze Z, Momma T, Ohki S, Saji S, Kono K.

Gan To Kagaku Ryoho. 2018 Oct;45(10):1539-1542. Japanese.

PMID:
30382071
31.

Poland syndrome accompanied by internal iliac artery supply disruption sequence: a case report.

Gonda K, Tachiya Y, Hatakeyama Y, Momma T, Tamaoki T, Maejima Y, Rokkaku Y, Saji S, Shimomura K, Kono K.

J Med Case Rep. 2018 Oct 26;12(1):312. doi: 10.1186/s13256-018-1823-8.

32.

Color-coded Imaging of the Circulating Tumor Cell Microenvironment.

Satake T, Suetsugu A, Nakamura M, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Oct;38(10):5635-5638. doi: 10.21873/anticanres.12898.

PMID:
30275181
33.

A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).

Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S.

J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766. doi: 10.4103/0973-1482.179188.

34.

Graphic Medicine and the Limits of Biostatistics.

Venkatesan S, Saji S.

AMA J Ethics. 2018 Sep 1;20(9):E897-901. doi: 10.1001/amajethics.2018.897.

35.

FTIR characterization of the setting reaction of biodentine™.

Alotaibi J, Saji S, Swain MV.

Dent Mater. 2018 Nov;34(11):1645-1651. doi: 10.1016/j.dental.2018.08.294. Epub 2018 Sep 12.

PMID:
30219594
36.

(Un)bridgeable Chasms?: Doctor-Patient Interactions in Select Graphic Medical Narratives.

Venkatesan S, Saji S.

J Med Humanit. 2019 Dec;40(4):591-605. doi: 10.1007/s10912-018-9528-y.

PMID:
30117008
37.

Color-coded Imaging Distinguishes Cancer Cells, Stromal Cells, and Recombinant Cancer-stromal Cells in the Tumor Microenvironment During Metastasis.

Nakamura M, Suetsugu A, Hasegawa K, Satake T, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Aug;38(8):4417-4423. doi: 10.21873/anticanres.12743.

PMID:
30061205
38.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S.

Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097.

PMID:
30020510
39.

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.

Kiso M, Tanaka S, Saji S, Toi M, Sato F.

Int J Cancer. 2018 Dec 1;143(11):2905-2918. doi: 10.1002/ijc.31645. Epub 2018 Oct 9.

40.

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1600. [Epub ahead of print]

41.

Evidence that metallic proxies are unsuitable for assessing the mechanics of microwear formation and a new theory of the meaning of microwear.

van Casteren A, Lucas PW, Strait DS, Michael S, Bierwisch N, Schwarzer N, Al-Fadhalah KJ, Almusallam AS, Thai LA, Saji S, Shekeban A, Swain MV.

R Soc Open Sci. 2018 May 23;5(5):171699. doi: 10.1098/rsos.171699. eCollection 2018 May.

42.

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration.

Takeuchi S, Yoshino T, Yamanaka T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.

Ann Oncol. 2018 Jun;29 Suppl 5:v110. doi: 10.1093/annonc/mdy149.027. Epub 2020 Jan 7. No abstract available.

43.

The long and winding road for overcoming resistance to hormone therapy in breast cancer.

Saji S.

Breast Cancer. 2018 Jul;25(4):377-378. doi: 10.1007/s12282-018-0876-2. No abstract available.

PMID:
29808354
44.

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.

ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018.

45.

Curcumin-galactomannoside complex inhibits pathogenesis in Ox-LDL-challenged human peripheral blood mononuclear cells.

Saji S, Asha S, Svenia PJ, Ratheesh M, Sheethal S, Sandya S, Krishnakumar IM.

Inflammopharmacology. 2018 Oct;26(5):1273-1282. doi: 10.1007/s10787-018-0474-0. Epub 2018 Apr 9.

PMID:
29633105
46.

Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.

Satake T, Suetsugu A, Nakamura M, Hasegawa K, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Apr;38(4):1927-1935.

PMID:
29599308
47.

Visualizing the Tumor Microenvironment by Color-coded Imaging in Orthotopic Mouse Models of Cancer.

Suetsugu A, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Apr;38(4):1847-1857. Review.

PMID:
29599301
48.

The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.

Takuwa H, Saji S, Takada M, Takahara S, Yamauchi A.

Breast Dis. 2018;37(4):185-190. doi: 10.3233/BD-170307.

PMID:
29578459
49.

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.

Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M, Maeda H, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.

Dis Colon Rectum. 2018 Jul;61(7):803-808. doi: 10.1097/DCR.0000000000001002.

50.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.

ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.

Supplemental Content

Support Center